Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn's disease and ulcerative colitis exacerbation

被引:67
作者
Moninuola, O. O. [1 ]
Milligan, W. [2 ]
Lochhead, P. [3 ]
Khalili, H. [3 ,4 ,5 ]
机构
[1] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA
[2] Univ Aberdeen, Aberdeen, Scotland
[3] Massachusetts Gen Hosp, Dept Med, Clin & Translat Epidemiol Unit, Boston, MA 02114 USA
[4] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA
[5] Harvard Med Sch, Boston, MA USA
关键词
INFLAMMATORY-BOWEL-DISEASE; SELECTIVE CYCLOOXYGENASE-2 INHIBITORS; CLINICAL RELAPSE; ASPIRIN; ROFECOXIB; INGESTION; SAFETY; COHORT; FLARES;
D O I
10.1111/apt.14606
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Unlike acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs) have generally been thought to be associated with increased risk of IBD exacerbation. Aim: To carry out a systematic review and meta-analysis of previous studies examining the association between acetaminophen and NSAIDs including cyclooxygenase (COX-2) inhibitors use, and risk of Crohn's disease (CD) and ulcerative colitis (UC) exacerbation. Methods: We identified published manuscripts and abstracts through 1 March 2017 by systematic search of Medline, Embase, Cochrane and other trial registries. Quality assessment was done using Newcastle-Ottawa scale and random-effect meta-analysis using pooled relative risks (RRs) and 95% CIs were calculated. Results: Eighteen publications between years 1983 and 2016 were identified. For the meta-analysis, pooled RRs of disease exacerbation with NSAIDs use were (1.42, 95% CI, 0.65-3.09), I-2=60.3% for CD, and (1.52, 95% CI, 0.87-2.63), I-2=56.1% for UC. The corresponding values for acetaminophen use were (1.40, 95% CI, 0.96-2.04), I-2=45.6% for UC, and (1.56, 95% CI, 1.22-1.99), I-2=0.0% for IBD. Sensitivity analyses limited to studies with low risk of bias showed a significantly increased risk of CD exacerbation (1.53, 95% CI, 1.08-2.16) but not UC (0.94, 95% CI, 0.36-2.42) with NSAIDs use. Conclusions: Contrary to generally accepted belief, we did not find a consistent association between NSAIDs use and risk of CD and UC exacerbation. There was also no consistent evidence for association with acetaminophen although further studies are needed.
引用
收藏
页码:1428 / 1439
页数:12
相关论文
共 53 条
[31]   Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease [J].
Kvasnovsky, Charlotte L. ;
Aujla, Usman ;
Bjarnason, Ingvar .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2015, 50 (03) :255-263
[32]  
Laine L, 1996, Gastrointest Endosc Clin N Am, V6, P489
[33]  
Liberati A, 2009, BMJ-BRIT MED J, V339, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b2700, 10.1186/2046-4053-4-1, 10.1136/bmj.i4086, 10.1136/bmj.b2535, 10.1016/j.ijsu.2010.02.007, 10.1016/j.ijsu.2010.07.299]
[34]   Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments [J].
Lo, Carson Ka-Lok ;
Mertz, Dominik ;
Loeb, Mark .
BMC MEDICAL RESEARCH METHODOLOGY, 2014, 14
[35]   Role of Nonsteroidal Anti-Inflammatory Drugs in Exacerbations of Inflammatory Bowel Disease [J].
Long, Millie D. ;
Kappelman, Michael D. ;
Martin, Christopher F. ;
Chen, Wenli ;
Anton, Kristen ;
Sandler, Robert S. .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2016, 50 (02) :152-156
[36]   Cognitive-behavioural interventions for children who have been sexually abused [J].
Macdonald, Geraldine ;
Higgins, Julian P. T. ;
Ramchandani, Paul ;
Valentine, Jeffrey C. ;
Bronger, Latricia P. ;
Klein, Paul ;
O'Daniel, Roland ;
Pickering, Mark ;
Rademaker, Ben ;
Richardson, George ;
Taylor, Matthew .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (05)
[37]  
Mahadevan U, 2002, AM J GASTROENTEROL, V97, P910
[38]   The pathophysiology of non-steroidal anti-inflammatory drug (NSAID)-induced mucosal injuries in stomach and small intestine [J].
Matsui, Hirofumi ;
Shimokawa, Osamu ;
Kaneko, Tsuyoshi ;
Nagano, Yumiko ;
Rai, Kanho ;
Hyodo, Lchinosuke .
JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION, 2011, 48 (02) :107-111
[39]   The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease [J].
Matuk, R ;
Crawford, J ;
Abreu, MT ;
Targan, SR ;
Vasiliauskas, EA ;
Papadakis, KA .
INFLAMMATORY BOWEL DISEASES, 2004, 10 (04) :352-356
[40]   Interrater reliability: the kappa statistic [J].
McHugh, Mary L. .
BIOCHEMIA MEDICA, 2012, 22 (03) :276-282